In 2010, Prostate Artery Embolization (PAE) was first described to diminish blood supply to the prostate and reduce its size. The clinical trials and the science backing PAE are explored in the September edition of the Journal of Vascular and Interventional Radiology. A number of studies reviewed in this JVIR consensus paper validate the efficacy of PAE in reducing urinary symptoms from BPH. When compared in a head-to-head study with TURP, both methods showed similar efficacy, with PAE providing the advantage of less bleeding and lower rates of urinary catheterization. PAE also does not require general anesthesia, imparts little pain, and is associated with minimal blood loss. While the authors note that PAE can be technically challenging to perform, quality of life scores following PAE show that patients are quite satisfied with the symptomatic relief that PAE provides when performed successfully. The authors conclude that current data regarding PAE shows promise.
To see the article in its entirety free of charge, click here.
To listen to a JVIR podcastinterview regarding this work, click here or visit JVIR on iTtunes.
Citation: McWilliams, J. P. et al. Society of Interventional Radiology Position Statement: Prostate Artery Embolization for Treatment of Benign Disease of the Prostate. Journal of Vascular and Interventional Radiology 25, 1349–1351 (2014).
Images: Bagla, S. et al. Early Results from a United States Trial of Prostatic Artery Embolization in the Treatment of Benign Prostatic Hyperplasia. Journal of Vascular and Interventional Radiology 25, 47–52 (2014).
Post author: Austin Bourgeois, MD